TOP TEN perturbations for 39792_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39792_at
Selected probe(set): 208766_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39792_at (208766_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-4.03374Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample
Relative Expression (log2-ratio):-3.2469301Number of Samples:3 / 3
Experimental | kidney transplantation study 16 (2 week) |
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal natural killer cell (CD56+) sample |
CD56+ natural killer cell samples derived from healthy control subjects. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-1.8529701Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)
Relative Expression (log2-ratio):-1.8034363Number of Samples:8 / 17
Experimental | pediatric septic shock study 3 (infant; subclass A) |
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
Control | normal blood sample (infant) |
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |
myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.7502537Number of Samples:5 / 3
Experimental | myotonic dystrophy study 4 (skeletal muscle; DM1) |
Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
Control | normal skeletal muscle tisuue (fetal) |
Commercially purchased normal fetal skeletal muscle tissue samples. |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-1.7009802Number of Samples:4 / 2
Experimental | renal cell carcinoma study 6 (chromophobe type) |
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
Control | normal kidney tissue (fetal) |
Normal fetal kidney tissue samples. |
hepatoblastoma study 1 (embryonal) / normal liver tissue
Relative Expression (log2-ratio):1.673131Number of Samples:7 / 5
Experimental | hepatoblastoma study 1 (embryonal) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-1.6289148Number of Samples:5 / 6
Experimental | colorectal adenoma study 2 |
Laser microdissected human adenoma sample. | |
Control | normal colon tissue |
Laser microdissected human colonic epithelial cells sample. |
hepatoblastoma study 1 (epithelial mixed) / normal liver tissue
Relative Expression (log2-ratio):1.55865Number of Samples:12 / 5
Experimental | hepatoblastoma study 1 (epithelial mixed) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):1.5354624Number of Samples:2 / 2
Experimental | T-cell activation study 4 |
T-cell samples antiCD3 activated for 30hrs. | |
Control | normal resting T-cell sample |
T cells resting for 30h. |